NCT05842954

Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria

A Randomized, Open-label, Multicenter Study to Compare Efficacy, Safety and Tolerability of KLU156 With Coartem® in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Adults and Children Followed by an Extension Phase With Repeated KLU156 Treatment

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,720 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 2 Months – 100 Years
• Healthy volunteers: Not accepted

Summary

This study aims to confirm the efficacy, safety and tolerability of KLU156, a fixed dose combination of ganaplacide (KAF156) and a solid dispersion formulation of lumefantrine (lumefantrine-SDF), when administered once daily for three days in adults and children ≥ 10 kg of body weight suffering from uncomplicated P. falciparum malaria (with or without other Plasmodium spp. co-infection). In the Extension phase, the safety, tolerability and efficacy of repeated treatment with KLU156 will be assessed for a maximum of two years in patients who did not experience early treatment failure (ETF), who did not experience any study treatment-related SAE (Serious Adverse Event) previously and who gave informed consent to participate in the Extension phase.

Detailed description

The purpose of this study is to confirm the efficacy, safety and tolerability of KLU156 in patients with uncomplicated P. falciparum malaria (with or without other Plasmodium spp. co-infection) by demonstrating that KLU156 is non-inferior to Coartem. * The study duration will be 43 days (Core phase) plus up to 24 months (Extension phase). * The treatment duration will be 3 days for each malaria episode. * The visit frequency will be Days 1-3 (hospitalized) and 5 follow-up visits (Days 4, 8, 22, 29 and 43) in the Core phase and Days 1-3 (hospitalized) and 3 follow-up visits (Days 4, 8 and 29) in the Extension phase. This study has two different primary outcomes depending on the submission (US New Drug Application (NDA) or non-US submissions).

Conditions

• Uncomplicated Plasmodium Falciparum Malaria

Interventions

Type	Name	Description
DRUG	KLU156	Oral use. KLU156 (400/480 mg) is the dose for patients with a bodyweight ≥ 35kg. Patients \< 35kg will take a fraction of the dose according to weight group as defined in the protocol.
DRUG	Coartem	Oral use. Dosing will be selected based on patient's body weight as per product's label.

Timeline

• Start date: 2024-03-07
• Primary completion: 2025-06-27
• Completion: 2025-11-25
• First posted: 2023-05-06
• Last updated: 2026-01-27

Locations

33 sites across 12 countries: Burkina Faso, Côte d’Ivoire, Democratic Republic of the Congo, Gabon, Ghana, Kenya, Mali, Niger, Rwanda, Tanzania, Uganda, Zambia